Corticosteroid-Induced Osteoporosis

Zelissen PMJ, Croughs RJM, van Rijk PP, et al. Effect of glucocorticoid replacement therapy on bone mineral density in patients with Addison disease. Ann Intern Med 1994; 120: 207–10 Ettinger B, Chidambaran P, Pressman A. Prevalence and determinants of osteoporosis drug prescription among patients with high exposure to glucocorticoid drugs. Am J Manag Care 2001; 7(6): 597–605 Walsh LJ, Wong CA, Pringle M, et al. Use of oral corticosteroids in the community and the prevention of secondary osteoporosis: a cross-sectional study. BMJ 1996; 313: 344–6 Lukert BP, Raisz LG. Glucocorticoid-induced osteoporosis: pathogenesis and management. Ann Intern Med 1990; 112(5): 352–64 Saito JK, Davis JW, Wasnich RD, et al. Users of low doses glucocorticoids have increased bone loss rates: a longitudinal study. Calcif Tissue Int 1995; 57: 115–9 Adachi JD, Bensen WG, Bell MJ, et al. Corticosteroid induced osteoporosis: follow-up over 3 years. In: Christiansen C, Overgaard K, editors. Osteoporosis 1990. Copenhagen: Osteopress ApS, 1990: 1745–7 Hahn TJ, Boisveau VC, Avioli LV. Effect of chronic corticosteroid administration on diaphyseal and metaphyseal bone mass. J Clin Endocrinol Metab 1974; 39: 274–82 Sambrook P, Birmingham J, Kelly P, et al. Prevention of corticosteroid osteoporosis: a comparison of calcium, calcitriol, and calcitonin. N Engl J Med 1993; 328(24): 1747–52 Adachi JD, Bensen WG, Brown J, et al. Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. N Engl J Med 1997; 337(6): 382–7 Baltzan MA, Suissa S, Bauer DC, et al. Hip fractures attributable to corticosteroid use. Lancet 1999; 353: 1327 van Staa TP, Leufkens HG, Abenhaim L, et al. Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. Rheumatology (Oxf) 2000; 39(12): 1383–9 Israel E, Banerjee TR, Fitzmaurice GM, et al. Effect of inhaled glucocorticoids on bone density in premenopausal women. N Engl J Med 2001; 345(13): 941–7 Jones A, Fay JK, Stone M, et al. Inhaled corticosteroid effects on bone metabolism in asthma and mild chronic obstructive pulmonary disease. Available in The Cochrane Library [database on disk and CD ROM]. Updated quarterly. The Cochrane Collaboration; issue 1. Oxford: Update Software, 2001 Schwid SR, Goodman AD, Puzas E, et al. Sporadic corticosteroid pulses and osteoporosis in multiple sclerosis. Arch Neurol 1996; 53: 753–7 Buckley LM, Marquez M, Feezor R, et al. Prevention of corticosteroid-induced osteoporosis: results of a patient survey. Arthritis Rheum 1999; 42(8): 1736–9 Hahn TJ, Hahn BH. Osteopenia in patients with rheumatic diseases: principles of diagnosis and therapy. Semin Arthritis Rheum 1976; 6: 165–88 Lukert BP, Adams JS. Calcium and phosphorus homeostasis in man: effect of corticosteroids. Arch Intern Med 1976; 136: 1249–53 Fucik RF, Kukreja SC, Hargis GK, et al. Effect of glucocorticoids on function of the parathyroid glands in man. J Clin Endocrinol Metab 1975; 40: 152–5 Pearce G, Tabensky DA, Delmas PD, et al. Corticosteroid-induced bone loss in men. J Clin Endocrinol Metab 1998; 83: 801–6 Williams GA, Bowser EN, Henderson WJ, et al. Calcium absorption in the rat in relation to excessive vitamin D and cortisone. Proc Soc Exp Biol Med 1960; 5: 354–8 Sjoberg HE. Retention of orally administered 47-calcium in man under normal diseased conditions studies with a whole-body counter technique. Acta Med Scand 1970; (509): 1-28 Favus NJ, Kimberg DV, Miller GN, et al. Effects of cortisone administration on the metabolism and localization of 25-hydroxycholecalciferol in the rat. J Clin Invest 1973; 52: 1328–35 Nielsen HK, Charles P, Moskelide L. The effect of single oral doses of prednisone on the circadian rhythm of serum osteocalcin in normal subjects. J Clin Endocrinol Metab 1988; 67: 1025–30 Manolagas SC, Weinstein RS. New developments in the pathogenesis and treatment of steroid-induced osteoporosis. J Bone Miner Res 1999; 14: 1061–6 Ishida Y, Heersche JNM. Glucocorticoid-induced osteoporosis: both in vivo and in vitro concentrations of glucocorticoids higher than physiological levels attenuate osteoblast differentiation. J Bone Miner Res 1998; 13: 1822–6 Dempster DW, Arlot MA, Meunier PJ. Mean wall thickness and formation periods of trabecular bone packets in corticosteroid-induced osteoporosis. Calcif Tissue Int 1983; 35(4–5): 410–7 Bressot C, Meunier PJ, Chapuy MC, et al. Histomorphometric profile, pathophysiology and reversibility of corticosteroid-induced osteoporosis. Metab Bone Dis Relat Res 1979; 1: 303–11 Chappard D, Legrand E, Basle MF, et al. Altered trabecular architecture induced by corticosteroids: a bone histomorphometric study. J Bone Miner Res 1996; 11(5): 676–85 Hahn TJ, Halstead LR, Teitelbaum SL, et al. Altered mineral metabolism in glucocorticoid induced osteopenia: effect of 25-hydroxyvitamin D administration. J Clin Invest 1979; 64: 655–65 Chesney RW, Mazess RB, Hamstra AJ. Reduction of serum 1,25-dihydroxyvitamin D in children receiving glucocorticoids. Lancet 1978; II: 1123–5 Godschalk M, Levy M, Downs RW. Glucocorticoids decrease vitamin D receptor numbers and gene expression in human osteosarcoma cells. J Bone Miner Res 1992; 7: 21–7 Sakakura M. Inhibition of luteinizing hormone secretion induced by synthetic LRH by long-term treatment with glucorticoids in human subjects. J Clin Endocrinol Metab 1975; 40: 774–9 Schaison G, Durand F, Nakagawa S. Effect of glucocorticoids on plasma testerone in men. Acta Endocrinol Metab 1987; 89: 126–31 Eastell R, Reid DM, Compston J, et al. A UK Consensus Group on management of glucocorticoid-induced osteoporosis: an update. J Intern Med 1998; 244(4): 271–92 Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: American College of Rheumatology Task Force on Osteoporosis guidelines. Arthritis Rheum 1996; 39: 1791-801 American College of Rheumatology Ad hoc committee on glucocorticoid-induced osteoporosis. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheum 2001; 44(7): 1496–503 Hart SR, Green B. Osteoporosis prophylaxis during corticosteroid treatment: failure to prescribe. Postgrad Med J 2002; 78: 242–3 Ross PD, Davis JW, Epstein RS, et al. Pre-existing fractures and bone mass predict vertebral fracture incidence in women. Ann Intern Med 1991; 114: 919–23 Czerwinski SM, Kurowski TG, O’Neill TM, et al. Initiating regular exercise protects against muscle atrophy from glucocorticoids. J Appl Physiol 1987; 63(4): 1504–10 Hickson RC, Kurowski TT, Andrews GH, et al. Glucocorticoid cytosol binding in exercise induced sparing of muscle atrophy. J Appl Physiol 1986; 60: 1413–9 Nelson ME, Fiatarone MA, Morganti CM, et al. Effects of high-intensity strength training on multiple risk factors for osteoporotic fractures: a randomized controlled trial. JAMA 1994; 272: 1909–14 Adachi JD, Bensen WG, Bianchi F, et al. Vitamin D and calcium in the prevention of corticosteroid induced osteoporosis: a 3 year follow-up. J Rheumatol 1996; 23(6): 995–1000 Reginster JY, Kuntz D, Verdickt W, et al. Prophylactic use of alfacalcidol in corticosteroid-induced osteporosis. Osteoporos Int 1999; 9: 75–81 Homik J, Suarez-Almazor ME, Shea B, et al. Calcium and vitamin D for corticosteroid-induced osteoporosis. Available in The Cochrane Library [database on disk and CD ROM]. Updated quarterly. The Cochrane Collaboration; issue 2. Oxford: Update Software, 2001: CD000952 Amin S, LaValley MP, Simms RW, et al. The role of vitamin D in corticosteroid-induced osteoporosis: a meta-analytic approach. Arthritis Rheum 1999; 42(8): 1740–51 Amin S, Lavalley MP, Simms RW, et al. The comparative efficacy of drug therapies used for the management of corticosteroid-induced osteoporosis: a meta-regression. J Bone Miner Res 2002; 17(8): 1512–26 Dykman TR, Haralson KM, Gluck OS, et al. Effect of oral 1,25 dihydroxyvitamin D and calcium on glucocorticoid-induced osteopenia in patients with rheumatic diseases. Arthritis Rheum 1984; 27: 1336–43 Plotkin LI, Weinstein RS, Parfitt AM, et al. Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin. J Clin Invest 1999; 104(10): 1363–74 Homik JE, Cranney A, Shea B, et al. A metaanalysis on the use of bisphosphonates in corticosteroid induced osteoporosis. J Rheumatol 1999; 26(5): 1148–57 Homik J, Cranney A, Shea B, et al. Bisphosphonates for steroid-induced osteoporosis. Available in The Cochrane Library [database on disk and CD ROM]. Updated quarterly. The Cochrane Collaboration; issue 2. Oxford: Update Software, 2002: CD001347 Saag KG, Emkey R, Schnitzer TJ, et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-induced Osteoporosis Intervention Study Group. N Engl J Med 1998; 339(5): 292–9 Jenkins EA, Walker-Bone KE, Wood A, et al. The prevention of corticosteroid induced osteoporosis with intermittent cyclical etidronate. Scand J Rheumatol 1999; 28: 152–6 Skingle SJ, Crisp AJ. Increased bone density in patients on steroids with etidronate. Lancet 1994; 344: 543–4 Roux C, Oriente P, Laan R, et al. Randomized trial of effect of cyclical etidronate in the prevention of corticosteroid-induced bone loss. Ciblos Study Group. J Clin Endocrinol Metab 1998; 83(4): 1128–33 Cohen S, Levy RM, Keller M, et al. Risedronate therapy prevents corticosteroid-induced bone loss. Arthritis Rheum 1999; 42: 2309–18 Boutsen Y, Jamart J, Esselinckx W, et al. Primary prevention of glucocorticoid-induced osteoporosis with intravenous pamidronate and calcium: a prospective controlled 1-year study comparing a single infusion, an infusion given once every 3 months, and calcium alone. J Bone Miner Res 2001; 16(1): 104–12 Gonnelli S, Rottoli P, Cepollaro C, et al. Prevention of corticosteroid-induced osteoporosis with alendronate in sarcoid patients. Calcif Tissue Int 1997; 61(5): 382–5 Mulder H, Struys A. Intermittent cyclical etidronate in the prevention of corticosteroid-induced bone loss. Br J Rheumatol 1994; 33(4): 348–50 Wolfhagen FH, van Buuren HR, Vleggaar FP, et al. Management of osteoporosis in primary biliary cirrhosis. Baillieres Best Pract Res Clin Gastroenterol 2000; 14(4): 629–41 Adachi JD, Saag KG, Delmas PD, et al. Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum 2001; 44(1): 202–11 Pitt P, Li F, Todd P, et al. A double blind placebo controlled study to determine the effects of intermittent cyclical etidronate on bone mineral density in patients on long term oral corticosteroid treatment. Thorax 1998; 53: 351–6 Worth H, Stammen D, Keck E. Therapy of steroid induced bone loss in adult asthmatics with calcium, vitamin D and a diphosphonate. Am J Respir Crit Care Med 1994; 150: 394–7 Reid IR, Heap SW, King AR, et al. Two-year follow-up of biphosphonate (APD) treatment in steroid osteoporosis [letter]. Lancet 1988; II(8620): 1144 Geusens P, Dequeker J, Vanhoof J, et al. Cyclical etidronate increases bone density in the spine and hip of postmenopausal women receiving long term corticosteroid treatment: a double blind randomised placebo controlled study. Ann Rheum Dis 1998; 57(12): 724–7 Reid DM, Hughes RA, Laan RFJM, et al. Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. J Bone Miner Res 2000; 15(6): 1006–13 Reid DM, Adami S, Devogelaer JP, et al. Risedronate increases bone density and reduces vertebral fracture risk within one year in men on corticosteroid therapy. Calcif Tissue Int 2001; 69: 242–7 Cranney A, Welch V, Adachi JD, et al. Calcitonin for the treatment and prevention of corticosteroid-induced osteoporosis. Available in The Cochrane Library [database on disk and CD ROM]. Updated quarterly. The Cochrane Collaboration; issue 2. Oxford: Update Software, 2000: CD001983 Luengo M, Pons F, Martinez de Osaba MJ, et al. Prevention of further bone mass loss by nasal calcitonin in patients on long term glucocorticoid therapy for asthma: a two year follow up study. Thorax 1994; 49(11): 1099–102 Ringe JD, Welzel D. Salmon calcitonin in the therapy of corticosteroid-induced osteoporosis. Eur J Clin Pharmacol 1987; 33: 35–9 Kotaniemi A, Piirainen H, Paimela L, et al. Is continuous intranasal salmon calcitonin effective in treating axial bone loss in patients with active rheumatoid arthritis receiving low dose glucocorticoied therapy? J Rheumatol 1996; 23: 1875–9 Healey JH, Paget SA, Williams-Russo P, et al. A randomized controlled trial of salmon calcitonin to prevent bone loss in corticosteroid-treated temporal arteritis and polymyalgia rheumatica. Calcif Tissue Int 1996; 58(2): 73–80 Hall GM, Daniels M, Doyle D, et al. Effect of hormone replacement therapy on bone mass in rheumatoid arthritis patients treated with and without steroids. Arthritis Rheum 1994; 37: 1499–505 Reid IR, Wattie DJ, Evans MC, et al. Testosterone therapy in glucocorticoid-treated men. Arch Intern Med 1996; 156: 1173–7 Adams JS, Wahl TO, Lukert BP. Effects of hydrochlorothiazide and dietary sodium restriction on calcium metabolism in corticosteroid treated patients. Metabolism 1981; 30: 217–21 Lems WF, Jacobs WG, Bijlsma JW, et al. Effect of sodium fluoride on the prevention of corticosteroid-induced osteoporosis. Osteoporos Int 1997; 7(6): 575–82 Lems WF, Jacobs JW, Bijlsma JW, et al. Is addition of sodium fluoride to cyclical etidronate beneficial in the treatment of corticosteroid induced osteoporosis? Ann Rheum Dis 1997; 56(6): 357–63 Meys E, Terreaux-Duvert F, Beaume-Six T, et al. Bone loss after cardiac transplantation: effects of calcium, calcidiol and monofluorophosphate. Osteoporos Int 1993; 3(6): 322–9 Lane NE, Sanchez S, Modin GW, et al. Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis: results of a randomized controlled clinical trial. J Clin Invest 1998; 102(8): 1627–33 Lane NE, Sanchez S, Modin G, et al. Bone mass continues to increase at the hip after parathyroid hormone treatment is discontinued in glucocorticoid-induced osteoporosis: results of a randomized controlled clinical trial. J Bone Miner Res 2000; (14): 944-51 Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001; 344(19): 1434–41 Adami S, Fossaluzza V, Rossini M, et al. The prevention of corticosteroid-induced osteoporosis with nandrolone decanoate. Bone Miner 1991; 15(1): 73–81